Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
9.600USD
+0.050+0.52%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
216.42MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.52%
5 Days
-5.97%
1 Month
+5.84%
6 Months
+33.52%
Year to Date
+30.43%
1 Year
+118.68%
Key Figures
9.700Open
9.959High
318.02KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.41%Turnover Ratio
9.550Prev. Close
9.450Low
2.12MTurnover
LossP/E Static
-0.81P/B
0.00%Div Yield TTM
-150.48%ROA
10.99052wk High
0.54Volume Ratio
-76.42MNet Profit
22.54MShares
-16.1748EPS TTM
0.83Beta
--ROE
3.65052wk Low
5.33%Amplitude
96.16%Gross Margin
216.42MMarket Cap
0.84Reward/Risk
6.30%Risk Rate
TradingKey Stock Score of Karyopharm Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Karyopharm Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.40.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Karyopharm Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Karyopharm Therapeutics Inc Highlights
StrengthsRisks
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 146.07M.
Fairly Valued
The company’s latest PE is -0.59, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.10M shares, increasing 26.39% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 27.91 shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.400
Target Price
+40.31%
Upside Space
Karyopharm Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Karyopharm Therapeutics Inc Info
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Ticker SymbolKPTI
CompanyKaryopharm Therapeutics Inc
CEOPaulson (Richard A)
Websitehttps://karyopharm.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Karyopharm Therapeutics Inc (KPTI)?
The current price of Karyopharm Therapeutics Inc (KPTI) is 9.60.
What is the symbol of Karyopharm Therapeutics Inc?
The ticker symbol of Karyopharm Therapeutics Inc is KPTI.
What is the 52-week high of Karyopharm Therapeutics Inc?
The 52-week high of Karyopharm Therapeutics Inc is 10.99.
What is the 52-week low of Karyopharm Therapeutics Inc?
The 52-week low of Karyopharm Therapeutics Inc is 3.65.
What is the market capitalization of Karyopharm Therapeutics Inc?
The market capitalization of Karyopharm Therapeutics Inc is 216.42M.
Is Karyopharm Therapeutics Inc (KPTI) currently rated as Buy, Hold, or Sell?
According to analysts, Karyopharm Therapeutics Inc (KPTI) has an overall rating of Buy, with a price target of 13.40.
What is the Earnings Per Share (EPS TTM) of Karyopharm Therapeutics Inc (KPTI)?
The Earnings Per Share (EPS TTM) of Karyopharm Therapeutics Inc (KPTI) is -17.93.